Perrigo Competitors

Johnson & Johnson (NYSE:JNJ) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk and analyst recommendations.

Volatility & Risk

Johnson & Johnson has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Institutional and Insider Ownership

67.3% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 82.7% of Perrigo shares are owned by institutional investors. 0.3% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.3% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Johnson & Johnson and Perrigo's revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has higher revenue and earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Johnson & Johnson and Perrigo's net margins, return on equity and return on assets.

Dividends

Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.5%. Perrigo pays an annual dividend of $0.96 per share and has a dividend yield of 2.3%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Perrigo pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and Perrigo has raised its dividend for 1 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Johnson & Johnson and Perrigo, as provided by MarketBeat.com.

Johnson & Johnson currently has a consensus price target of $180.6429, indicating a potential upside of 11.85%. Perrigo has a consensus price target of $52.00, indicating a potential upside of 26.55%. Given Perrigo's higher probable upside, analysts clearly believe Perrigo is more favorable than Johnson & Johnson.

Summary

Johnson & Johnson beats Perrigo on 12 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.

Institutional & Insider Ownership

67.4% of Pfizer shares are owned by institutional investors. Comparatively, 82.7% of Perrigo shares are owned by institutional investors. 0.1% of Pfizer shares are owned by company insiders. Comparatively, 0.3% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Pfizer and Perrigo, as provided by MarketBeat.com.

Pfizer currently has a consensus price target of $38.5714, suggesting a potential upside of 2.75%. Perrigo has a consensus price target of $52.00, suggesting a potential upside of 26.55%. Given Perrigo's higher probable upside, analysts plainly believe Perrigo is more favorable than Pfizer.

Risk and Volatility

Pfizer has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Profitability

This table compares Pfizer and Perrigo's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Pfizer and Perrigo's gross revenue, earnings per share (EPS) and valuation.

Pfizer has higher revenue and earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Dividends

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.2%. Perrigo pays an annual dividend of $0.96 per share and has a dividend yield of 2.3%. Pfizer pays out 52.9% of its earnings in the form of a dividend. Perrigo pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has raised its dividend for 1 consecutive years and Perrigo has raised its dividend for 1 consecutive years.

Summary

Pfizer beats Perrigo on 10 of the 16 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. Perrigo pays an annual dividend of $0.96 per share and has a dividend yield of 2.3%. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Perrigo pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has raised its dividend for 1 consecutive years and Perrigo has raised its dividend for 1 consecutive years.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Merck & Co., Inc. and Perrigo, as reported by MarketBeat.

Merck & Co., Inc. presently has a consensus target price of $96.2727, indicating a potential upside of 25.85%. Perrigo has a consensus target price of $52.00, indicating a potential upside of 26.55%. Given Perrigo's higher possible upside, analysts clearly believe Perrigo is more favorable than Merck & Co., Inc..

Profitability

This table compares Merck & Co., Inc. and Perrigo's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Merck & Co., Inc. and Perrigo's top-line revenue, earnings per share (EPS) and valuation.

Merck & Co., Inc. has higher revenue and earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Merck & Co., Inc. has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.

Institutional and Insider Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 82.7% of Perrigo shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 0.3% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Merck & Co., Inc. beats Perrigo on 11 of the 16 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Perrigo (NYSE:PRGO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.9%. Perrigo pays an annual dividend of $0.96 per share and has a dividend yield of 2.3%. AbbVie pays out 58.2% of its earnings in the form of a dividend. Perrigo pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has raised its dividend for 49 consecutive years and Perrigo has raised its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares AbbVie and Perrigo's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares AbbVie and Perrigo's revenue, earnings per share (EPS) and valuation.

AbbVie has higher revenue and earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

AbbVie has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for AbbVie and Perrigo, as provided by MarketBeat.

AbbVie presently has a consensus price target of $115.75, suggesting a potential upside of 8.44%. Perrigo has a consensus price target of $52.00, suggesting a potential upside of 26.55%. Given Perrigo's higher probable upside, analysts plainly believe Perrigo is more favorable than AbbVie.

Insider & Institutional Ownership

67.5% of AbbVie shares are owned by institutional investors. Comparatively, 82.7% of Perrigo shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.3% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

AbbVie beats Perrigo on 12 of the 17 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Volatility & Risk

Eli Lilly and has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Dividends

Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.8%. Perrigo pays an annual dividend of $0.96 per share and has a dividend yield of 2.3%. Eli Lilly and pays out 56.3% of its earnings in the form of a dividend. Perrigo pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and has increased its dividend for 1 consecutive years and Perrigo has increased its dividend for 1 consecutive years. Perrigo is clearly the better dividend stock, given its higher yield and lower payout ratio.

Earnings and Valuation

This table compares Eli Lilly and and Perrigo's top-line revenue, earnings per share (EPS) and valuation.

Eli Lilly and has higher revenue and earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Eli Lilly and and Perrigo, as provided by MarketBeat.

Eli Lilly and presently has a consensus price target of $196.40, suggesting a potential upside of 5.52%. Perrigo has a consensus price target of $52.00, suggesting a potential upside of 26.55%. Given Perrigo's higher probable upside, analysts clearly believe Perrigo is more favorable than Eli Lilly and.

Insider & Institutional Ownership

75.6% of Eli Lilly and shares are held by institutional investors. Comparatively, 82.7% of Perrigo shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by insiders. Comparatively, 0.3% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Eli Lilly and and Perrigo's net margins, return on equity and return on assets.

Summary

Eli Lilly and beats Perrigo on 10 of the 16 factors compared between the two stocks.

Perrigo (NYSE:PRGO) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Profitability

This table compares Perrigo and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Perrigo and Bristol-Myers Squibb, as reported by MarketBeat.

Perrigo presently has a consensus price target of $52.00, indicating a potential upside of 26.55%. Bristol-Myers Squibb has a consensus price target of $74.60, indicating a potential upside of 15.44%. Given Perrigo's higher possible upside, analysts plainly believe Perrigo is more favorable than Bristol-Myers Squibb.

Risk & Volatility

Perrigo has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.

Institutional and Insider Ownership

82.7% of Perrigo shares are held by institutional investors. Comparatively, 72.4% of Bristol-Myers Squibb shares are held by institutional investors. 0.3% of Perrigo shares are held by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Perrigo and Bristol-Myers Squibb's revenue, earnings per share (EPS) and valuation.

Bristol-Myers Squibb has higher revenue and earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Dividends

Perrigo pays an annual dividend of $0.96 per share and has a dividend yield of 2.3%. Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.0%. Perrigo pays out 23.8% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Perrigo has raised its dividend for 1 consecutive years and Bristol-Myers Squibb has raised its dividend for 1 consecutive years.

Summary

Bristol-Myers Squibb beats Perrigo on 12 of the 17 factors compared between the two stocks.